Knowledge Hub

Inherited Orphan Blood Disorders Therapeutics Market To 2019 - Breakthrough Drugs Remain Elusive Against Backdrop Of High Unmet Need

Press Release   •   Nov 22, 2016 06:05 EST


GBI Research, the leading business intelligence provider, has released its latest research, Inherited Orphan Blood Disorders Therapeutics Market to 2019 Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need. The report provides insights into the up-and-coming trends of a portion of the inherited orphan blood disorder pharmaceutical market by examining sickle cell anemia, thalassemia and Hereditary Angioedema (HAE) in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan. The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts.

The sickle cell anemia market will be the fastest growing of the three markets during the forecast period with a Compound Annual Growth Rate (CAGR) of 9% seeing it reach $70m in 2019. The thalassemia market will grow at a lower CAGR of 7% to reach $59m in 2019. HAE represents the largest but slowest growing market, expected to reach $1.89 billion by 2019 at a CAGR of 3%


Current and future treatment trends for three rare diseases

Market forecasts for three rare diseases across seven major markets

Analysis of the developmental pipelines for three rare diseases

Information on recent industry deals

Download Sample Copy of Report at

Reasons to buy

Understand how the inherited orphan blood diseases market has developed and is continuing to develop within the featured markets

Predict which products are likely to be most successful in the future

Gain an understanding of the possible market available for specific products

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 6

2 Inherited Orphan Blood Diseases - Introduction 8

2.1 Overview 8

3 Inherited Orphan Blood Disorders - Therapeutic Landscape 9

3.1 Sickle Cell Anemia 9

3.1.1 Disease Overview 9

3.1.2 Revenues 14

3.1.3 Revenue Analysis by Country 14

3.1.4 Annual Cost of Therapy 18

3.1.5 Treatment Usage Patterns 19

3.1.6 Marketed Products 20

3.1.7 Market Drivers 21

3.1.8 Market Restraints 21

3.2 Sickle Cell Anemia: Research and Development Pipeline 22

3.2.1 Overview 22

3.2.2 Pipeline by Clinical Phase of Development 23

3.2.3 Trends in Sickle Cell Anemia Pipeline 28

3.2.4 Promising Pipeline Molecules 30

3.2.5 Key Takeaway 32

3.3 Thalassemia 33